While Pfizer and Merck grab headlines, Prasco has quietly built a $53.7M revenue engine by solving the one problem big pharma won't touch: making sure patients can actually get their generic medications. This isn't a startup story—it's a precision strike on the supply chain gaps that cost lives.

"Prasco doesn't compete on volume—they compete on solving the specific drug shortages that make pharmacists and patients desperate."

The leadership structure tells you everything about their operational focus. With both Christopher Arington and Philip Arington in C-suite roles plus Thomas Arington as Founder and Chairman, this is a family-built operation that values execution over fundraising. They've grown to 267 employees without external funding disclosures, suggesting either bootstrapped discipline or strategic reinvestment that venture-backed companies rarely achieve.

• Patient assistance programs are a core search driver (180 monthly searches for 'prasco patient assistance program')
• They own the 'generic Cymbalta' conversation (320 monthly searches asking if Prasco makes it)
• Direct traffic dominance suggests they've built a B2B moat, not just a consumer brand